Dysfunctional adipose tissue actively drives erectile dysfunction through multiple molecular mechanisms including reduced nitric oxide bioavailability, increased vascular stiffness, disrupted neuroendocrine signaling, and cavernosal fibrosis. The research identifies specific processes like inflammation, cellular senescence, extracellular vesicle signaling, ferroptosis, and mitochondrial dysfunction across visceral, perivascular, and periprostatic fat depots that directly impair erectile function. This reframes obesity's role from passive association to active causation in sexual dysfunction. The finding carries significant implications for men's health, suggesting that targeting adipose dysfunction could provide disease-modifying treatments rather than symptomatic management. Current erectile dysfunction treatments focus on downstream vascular effects, but this framework points toward upstream interventions including senolytics to clear senescent fat cells and extracellular vesicle modulation. The research validates why weight loss consistently improves erectile function and opens therapeutic avenues beyond traditional phosphodiesterase inhibitors. This represents a paradigm shift from viewing erectile dysfunction as primarily vascular to understanding it as fundamentally metabolic, with adipose tissue orchestrating systemic dysfunction that manifests in sexual health.